Autres langues BeiGene, Ltd.

Actions

BGNE

US07725L1026

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
153,6 ^USD	+3,38 %		+18,58 %	-14,85 %

23/04	Mise à jour sectorielle : Les actions du secteur des soins de santé augmentent dans les échanges de l'après-midi	MT
23/04	BeiGene annonce que le tislelizumab a reçu l'approbation de la Commission européenne pour le traitement du cancer du poumon non à petites cellules ; les actions augmentent	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BeiGene : Financial Information - Form 8-K	26/04
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report	26/04
Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	25/04
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	24/04
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	24/04
Sector Update: Health Care Stocks Rise in Afternoon Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	23/04
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	23/04
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	23/04
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
BeiGene to Award Shares Worth $15 Million to 11 Directors	17/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	10/04
Beigene Shrinks Loss by 56% in 2023	29/03
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	22/03
BeiGene, Ltd. Announces Executive Changes	20/03
BeiGene recibe la aprobación de la FDA para TEVIMBRA ® para el tratamiento del carcinoma esofágico de células escamosas avanzado o metastásico luego de una quimioterapia previa	15/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BeiGene, Ltd.

Actions

BGNE

US07725L1026

Autres langues

Filtres